General Oncology

Focus: General Oncology is a Boston-area biotechnology company founded in 1990 specializing in cancer therapies across multiple oncology indications. The company operates as a mid-cap biotech with a focused pipeline spanning early-stage and clinical-phase programs.

Oncology

Profile data last refreshed 5h ago · AI intelligence enriched 2w ago

Open Jobs

Should You Work at General Oncology?

AI assessment

General Oncology is a niche oncology biotech with a substantial pipeline but limited hiring momentum and opaque financial health—evaluate only if you have strong cancer drug development interest and accept execution risk.

Why Work Here

Established 34-year history in oncology with deep disease focus across solid tumors and hematologic malignancies

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Late-stage

4 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Personalized surveillance and intervention protocol

Familial Adenomatous Polyposis

N/A

Clinical Trials (1)

NCT04678011A Personalized Surveillance and Intervention Protocol for Patients With Familial Adenomatous Polyposis That Have Undergone (Procto)Colectomy

N/A

Help build intelligence for General Oncology

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diversified pipeline of 30 programs spanning Phase 1 through Phase 4, including combination immunotherapy approaches and novel modalities

Located in Boston biotech hub (Brookline, MA) with access to academic medical centers and established network effects

Watch Out For

Only 1 active job opening reported, suggesting limited near-term hiring and constrained growth trajectory
Pipeline composition skews heavily toward early-stage work (2 Phase 1 programs) with unclear clinical progression metrics and limited published data (0 publications)
No disclosed revenue, funding stage, or public financial data indicates private status with unknown capitalization or cash runway

Generated by Claude from General Oncology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Standard Palliative Care Group

Non-small Cell Lung Cancer

N/A

Clinical Trials (1)

NCT01038271Integrated Versus Standard Palliative Care in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

N/A

No intervention

Prostate Cancer

N/A

Clinical Trials (1)

NCT01813370A Registry for Patients Treated on the Clinical Trial TAX 3503

N/A

Stents

Deep Vein Thrombosis

N/A

Clinical Trials (1)

NCT03250247Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)

N/A

Blood and Tissue Collection

Cutaneous Squamous Cell Carcinoma

N/A

Clinical Trials (1)

NCT06875609ctDNA in Cutaneous Squamous Cell Carcinoma

N/A

Accelerated Proton Beam Radiation Therapy

Breast Cancer

N/A

Clinical Trials (1)

NCT05912231Ultrahypofractionation and Normal Tissue Toxicity

N/A

Psychometric Properties of the Updated Module on Assessing Quality of Life of Patients With Breast C

Breast Cancer

N/A

Clinical Trials (1)

NCT04018235Psychometric Properties of the Updated Module on Assessing Quality of Life of Patients With Breast Cancer

N/A

Early Detection of Five Common Cancers Using the ctDNA Analysing Test

Cancer, Lung

N/A

Clinical Trials (1)

NCT05227261Early Detection of Five Common Cancers Using the ctDNA Analysing Test

N/A

Support provided by social worker

Breast Cancer

N/A

Clinical Trials (1)

NCT02626377Multicenter Prospective Cohort of Informal Caregivers in Burgundy and Franche-Comté

N/A

International PPB/DICER1 Registry

Pleuropulmonary Blastoma

N/A

Clinical Trials (1)

NCT03382158International PPB/DICER1 Registry

N/A

A Predictive Score for Arterial Thrombosis Associated With Cancer

Cancer

N/A

Clinical Trials (1)

NCT05256329A Predictive Score for Arterial Thrombosis Associated With Cancer

N/A

Carboplatin/Cisplatin -Etoposide - Atezolizumab

Small Cell Lung Cancer

N/A

Clinical Trials (1)

NCT06717243Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)

N/A

Quality of Life Intervention

Quality of Life

N/A

Clinical Trials (1)

NCT05853614Nurse-Led Quality of Life Study-Phase I

N/A

Personalized surveillance and intervention protocol

Familial Adenomatous Polyposis

N/A

Clinical Trials (1)

NCT04677998A Personalized Surveillance and Intervention Protocol for Duodenal and Gastric Polyposis in Patients With Familial Adenomatous Polyposis

N/A

Health Professional Consortium

Geriatrics

N/A

Clinical Trials (1)

NCT05423808Geriatric and Oncological Evaluation With Technology for Holistic Healthcare Management for Older Multimorbid Patients.

N/A

A Novel Method of Screening for Ovarian Cancer Using Gynecologic Fluids and Mucus

Ovarian Cancer

N/A

Clinical Trials (1)

NCT01787656A Novel Method of Screening for Ovarian Cancer Using Gynecologic Fluids and Mucus

N/A

IMPROVED intervention

Cancer

N/A

Clinical Trials (1)

NCT03396510Electronic Symptom Monitoring Intervention for Hospitalized Patients With Cancer

N/A

Paxman Limb Cryocompression System

Chemotherapy-induced Peripheral Neuropathy

N/A

Clinical Trials (1)

NCT05606068A Novel Limb Cryocompression System for Prevention of Chemotherapy Induced Peripheral Neuropathy - Expansion Study

N/A

Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy i

Pancreatic Cancer

N/A

Clinical Trials (1)

NCT04112836Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer

N/A

A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna Gen

Breast Cancer

N/A

Clinical Trials (1)

NCT01899079A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna Gene Signature Assay

N/A

Lactoferrin

Anemia

Phase 1

Clinical Trials (1)

NCT03683810The Effectiveness of Lactoferrin in the Management of Treatment-induced Anemia

Phase 1

Ziftomenib

KMT2A-rearranged

Phase 1

Clinical Trials (1)

NCT07355335Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML

Phase 1

Melphalan

Pancreatic Adenocarcinoma Metastatic

Phase 1

Clinical Trials (1)

NCT04150042SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

Phase 1

TAS-102

Colorectal Cancer

Phase 1/2

Niraparib

Ovarian Cancer

Phase 1/2

bevacizumab

Breast Cancer

Phase 2

Clinical Trials (1)

NCT00670982Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer

Phase 2

Toripalimab-tpzi

Squamous Cell Carcinoma

Phase 2

Clinical Trials (1)

NCT07214987PDT For Induction Therapy For Head And Neck Cancer

Phase 2

HA-Irinotecan

Metastatic Colorectal Cancer

Phase 2

Bevacizumab

Esophageal Cancer

Phase 2

Clinical Trials (1)

NCT00911820Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer

Phase 2

Campath-1H

Lymphoplasmacytic Lymphoma

Phase 2

Clinical Trials (1)

NCT00142181Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia

Phase 2

Bortezomib

Plasma Cell Leukemia

Phase 2

Clinical Trials (1)

NCT01328236Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia

Phase 2

Doxorubicin

Breast Cancer

Phase 2

Clinical Trials (1)

NCT00546156Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer

Phase 2

HA-WBRT

Brain Metastases

Phase 2

Clinical Trials (1)

NCT04452084Phase 2 Trial in Multiple Brain Metastases Outcomes With HA-SIB-WBRT

Phase 2

Zoledronic acid

Multiple Myeloma

Phase 2

Clinical Trials (1)

NCT00577642Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates

Phase 2

Radiotherapy

Glioblastoma Multiforme

Phase 3

Clinical Trials (1)

NCT01450449Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme

Phase 3

Tailored antibiotic and steroid therapy based on the IL-6 value in amniotic fluid obtained by amniocentesis in patients with premature rupture of membranes

Preterm Premature Rupture of Membranes (PPROM)

Phase 3

Clinical Trials (1)

NCT07107477TAILORED Therapeutic Regime in Patients With Preterm Premature Rupture Of Membranes to Prolong Pregnancy, Improve Maternal and Neonatal Outcomes, and Reduce Antibiotic Burden

Phase 3

Recombinant tissue plasminogen activator

Deep Vein Thrombosis

Phase 3

Gemcitabine

Sarcoma, Soft Tissue

Phase 3

Clinical Trials (1)

NCT00142571Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma

Phase 3

Rabbit ATG,

Aplastic Anemia